Trendlines and Shoushan Wealth form joint venture to pave way for medical and agricultural company in China

Wed Aug 23, 2017 - 9:01am GMT+0000
Trendlines, Shoushan
Trendlines and Shoushan Wealth form joint venture to pave way for medical and agricultural company in China

Trendlines, Shoushan

SGX-listed Trendlines Group, an Israeli medical technology incubator that focuses on the development and commercialization of medical and agricultural technologies has together with Chinese PE firm Shoushan Wealth Holdings set up a joint venture.

The JV company which date of execution on term sheet was announced on December 16, 2016 is known as China – Israel New Trend (Taizhou) Medical Technology Co. Ltd. and will be headquartered in Shanghai, with additional staffs based in Israel.

Trendlines is an Israeli and Singapore-based incubator that invests and nurtures early stage medical and agricultural technology companies. This partnership will help Trendlines’ portfolio companies as well as other medical companies to penetrate into the Chinese market.

This includes supporting companies in establishing their manufacturing capabilities in China, obtaining regulatory approval for the sale of products in China, and managing the company’s’ strategic partner relationships.

Zhang Jun, the CEO of Shoushan said, “Being deeply networked in the Chinese economy, Shoushan sees the opportunity in China for innovative medical solutions, but also challenges that foreign companies experience in penetrating our market.”

“This joint venture will engage the best innovative medical technology companies and offer, through the combined strength of our JV to provide a unique way into China, creating tremendous value for all,” Zhang said.

Based in Shanghai with operation centers in Shenzhen, Beijing, and other locations in China, Shoushan helps provide a comprehensive wealth-management service for high-net-worth individuals, families, and enterprises.

Additionally, Trendlines and Shoushan also intend to raise two venture funds in US dollar and Chinese RMB to invest in global medical technology companies.

Todd Dollinger, the Chairman and CEO of Trendlines said: “Trendlines sees the Chinese market as critical to maximizing the success of our portfolio companies. Our work with Shoushan is part of Trendlines’ dedication to supporting and developing our companies in China.”

At present, Trendlines has 46 portfolio companies including advanced membrane technologies Mem-tech and renewable energy for low power devices SolChip, among some who has received awards by Israel’s Office of the Chief Scientist of the Ministry of Economy.

On Tuesday, Trendlines Group shares has moved on volatility 6.57% or 0.009 from the open. The company also saw a recent bid of 0.146 and 170,800 shares traded hands in the session.